clinical trial · NCT00689104
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Urinary Bladder, OveractiveMirabegronTolterodinePlacebo to MirabegronPlacebo to Tolterodine
brief summary
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
started
Apr 28, 2008
primary completion
Mar 24, 2009
completion
Mar 24, 2009
last updated
Nov 20, 2024
official title
A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol